Anticancer carrier-linked prodrugs in clinical trials

被引：75

作者：

Kratz, Felix ^{[1
]}

Abu Ajaj, Khalid ^{[1
]}

Warnecke, Andre ^{[1
]}

机构：

[1] Tumor Biol Ctr, Macromol Prodrugs, D-79106 Freiburg, Germany

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 07期

关键词：

antibodies; anticancer prodrugs; cancer chemotherapy; drug targeting; polymer therapeutics;

D O I：

10.1517/13543784.16.7.1037

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Coupling of low molecular weight anticancer drugs to antibodies, serum proteins or polymers through a cleavable linker has been an effective method for improving the therapeutic index of cytotoxic established agents. Modern drug-antibody conjugates that have recently entered clinical trials have primarily used highly potent drugs such as calicheamicin or maytansins. Gemtuzumab ozogamicin, a conjugate of calicheamicin and an anti-CD33 humanized antibody, is the first drug-antibody conjugate to receive market approval. Drug conjugates that have undergone clinical assessment include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates with doxorubicin, camptothecin, paclitaxel and Pt(II) complexes, poly(ethylene glycol) conjugates with camptothecin and paclitaxel, polyglutamate conjugates with paclitaxel and camptothecin, a methotrexate-albumin conjugate and an albumin-binding doxorubicin prodrug. This review summarizes the Phase I - III studies that have been performed with these macromolecular prodrugs.

引用

页码：1037 / 1058

页数：22

共 82 条

[1] Monoclonal antibodies for the treatment of acute myeloid leukemia [J].

Abutalib, Syed A. ;

Tallman, Martin S. .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) :343-369

[2]

Ajani JA, 2000, CANCER J, V6, P78

[3] PIONEER: A phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2 [J].

Albain, Kathy S. ;

Belani, Chandra P. ;

Bonomi, Philip ;

O'Byrne, Kenneth J. ;

Schiller, Joan H. ;

Socinski, Mark .

CLINICAL LUNG CANCER, 2006, 7 (06) :417-419

[4]

Beeram M, 2002, P AN M AM SOC CLIN, V21, P405

[5]

Bilim V, 2003, CURR OPIN MOL THER, V5, P326

[6] Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148):: a polymeric derivative of camptothecin (CPT) [J].

Bissett, D ;

Cassidy, J ;

de Bono, JS ;

Muirhead, F ;

Main, M ;

Robson, L ;

Fraier, D ;

Magnè, ML ;

Pellizzoni, C ;

Porro, MG ;

Spinelli, R ;

Speed, W ;

Twelves, C .

BRITISH JOURNAL OF CANCER, 2004, 91 (01) :50-55

[7] A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules [J].

Boddy, AV ;

Plummer, ER ;

Todd, R ;

Sludden, J ;

Griffin, M ;

Robson, L ;

Cassidy, J ;

Bissett, D ;

Bernareggi, A ;

Verrill, MW ;

Calvert, AH .

CLINICAL CANCER RESEARCH, 2005, 11 (21) :7834-7840

[8] Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma [J].

Bolling, C. ;

Graefe, T. ;

Luebbing, C. ;

Jankevicius, F. ;

Uktveris, S. ;

Cesas, A. ;

Meyer-Moldenhauer, W. -H. ;

Starkmann, H. ;

Weigel, M. ;

Burk, K. ;

Hanauske, A. -R. .

INVESTIGATIONAL NEW DRUGS, 2006, 24 (06) :521-527

[9]

Bross PF, 2001, CLIN CANCER RES, V7, P1490

[10]

Burke TG, 2000, ANN NY ACAD SCI, V922, P36

← 1 2 3 4 5 6 7 8 9 →